Clinical Benefit of Mepolizumab in Eosinophilic Granulomatosis With Polyangiitis for Patients With and Without a Vasculitic Phenotype.
Benjamin TerrierDavid R W JayneBernhard HellmichJane H BentleyJonathan SteinfeldSteven W YanceyNamhee KwonPraveen AkuthotaPaneez KhouryLee BaylisMichael E Wechslernull nullPublished in: ACR open rheumatology (2023)
Mepolizumab is associated with clinical benefits for patients with and without a vasculitic EGPA phenotype.
Keyphrases